Skip to main content
SpringerLink
Log in

Beta-Blockers for Hypertension in Asian Population

  • Chapter
  • First Online:
Hypertension and Cardiovascular Disease in Asia

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

  • 689 Accesses

Abstract

Asian countries are seeing an increasing trend in its hypertensive population, particularly among the low-income and middle-income countries. This may be attributed to their acculturation to Western lifestyle and urbanization. Western hypertension guidelines are relatively more established than Asian guidelines but before adopting them into clinical practice among Asian countries, the unique features of Asian patients should be considered. Selecting appropriate BP-lowering drugs is a challenge in Asian populations because of the lack of existing Asia-specific data. Effective blood pressure lowering reduces overall cardiovascular morbidity and mortality in patients, yet, there have been doubts regarding the utility of beta-blockers (mainly older generation) as initial hypertension therapy. However, beta-blockers have been known to play a particular role among hypertensive patients especially those with concomitant heart failure, coronary artery disease, and those with increased sympathetic activity among others. Studies identifying genetic polymorphisms found in the different ethnic groups in the Asian population also give light as to the differences in this class of drug’s pharmacodynamic responses in certain groups. The growing studies showing the better hemodynamic and metabolic profile of the newer generation of beta-blockers could potentially further encourage more use of this class of drug in the Asian population.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Forouzanfar MH, Liu P, Roth GA, Ng M, Birukov S, Marczak L, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mmHg, 1990-2015. JAMA. 2017;317:165–82.

    Article  Google Scholar 

  2. Kim CH, Abelardo N, Buranakitjaroen P, Krittayaphong R, Lim CH, Park SH, Pham NV, Rogelio G, Wong B, Low LP. Hypertension treatment in the Asia-Pacific: the role of and treatment strategies with nebivolol. Heart Asia. 2016;8(1):22–6. https://doi.org/10.1136/heartasia-2015-010656. PMID: 27326226; PMCID: PMC4898626.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chiang CE, Chen CH. Hypertension in the Asia-Pacific region. J Hum Hypertens. 2008;22:441–3.

    Article  Google Scholar 

  4. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in blood pressure from 1975 to 2015: a pooled analysis 1479 population-based measurement studies with 19.1 million participants. Lancet. 2017;389:37–55.

    Article  Google Scholar 

  5. Baker JG, Hill SJ, Summers RJ. Evolution of β-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci. 2011;32:227–34.

    Article  CAS  Google Scholar 

  6. Wiysonge CS, Opie LH. β-Blockers as initial therapy for hypertension. JAMA. 2013;310:1851–2.

    Article  CAS  Google Scholar 

  7. Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545–53.

    Article  CAS  Google Scholar 

  8. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet. 2007;369:201–7.

    Article  CAS  Google Scholar 

  9. De Caterina AR, Leone AM. Why beta-blockers should not be used as first choice in uncomplicated hypertension. Am J Cardiol. 2010;105:1433–8.

    Article  Google Scholar 

  10. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121–58.

    Article  CAS  Google Scholar 

  11. Chrysant SG, Chrysant GS. Current status of β-blockers for the treatment of hypertension: an update. Drugs Today (Barc). 2012;48:353–66.

    Article  CAS  Google Scholar 

  12. Williams S, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021–104.

    Article  Google Scholar 

  13. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFÉ) study. Circulation. 2006;113(9):1213–25.

    Article  CAS  Google Scholar 

  14. Bakris GL, Fonseca V, Katholi RE, McGill JB, Messerli FH, Phillips RA, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JAMA. 2004;292:2227–36.

    Article  CAS  Google Scholar 

  15. Ayers K, Byrne LM, DeMatteo A, Brown NJ. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59:893–8.

    Article  CAS  Google Scholar 

  16. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb CD, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71:e13–e115. https://doi.org/10.1161/HYP.0000000000000065.

    Article  CAS  PubMed  Google Scholar 

  17. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension. 2020;75:1334–57. https://doi.org/10.1161/HYPERTENSIONAHA.120.15026.

    Article  CAS  PubMed  Google Scholar 

  18. James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. Evidence-based guideline for the management of high blood pressure in adults report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; https://doi.org/10.1001/jama.2013.284427.

  19. National Guideline Centre (UK). Hypertension in adults: diagnosis and management. London: National Institute for Health and Care Excellence (UK); 2019.

    Google Scholar 

  20. Park JB. Asian guidelines on hypertension. Pulse. 2015;3(1):12–3. https://doi.org/10.1159/000381967.

    Article  PubMed Central  Google Scholar 

  21. Angeli F, Reboldi G, Verdecchia P. The 2014 hypertension guidelines: implications for patients and practitioners in Asia. Heart Asia. 2015;7:21–5. https://doi.org/10.1136/heartasia-2015-010639.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Lee HY, Shin J, Kim GH, Park S, Ihm S, Kim HC, et al. 2018 Korean Society of Hypertension Guidelines for the management of hypertension: part II-diagnosis and treatment of hypertension. Clin Hypertens. 2019;25:20.

    Article  Google Scholar 

  23. Chiang CE, Wang T, Ueng K, Lin T, Yeh H, Chen C, et al. 2015 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension. J Chin Med Assoc. 2014; https://doi.org/10.1016/j.jcma.2014.11.005.

  24. Liu L, Wu Z, Wang J, Wang W, Bao Y, Cai J, et al. 2018 Chinese guidelines for prevention and treatment of hypertension—a report of the revision Committee of Chinese Guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16:182–241. https://doi.org/10.11909/j.issn.1671-5411.2019.03.014.

    Article  Google Scholar 

  25. Shin J, Choi YJ, Hong GR, Jeon DW, Kim DH, Koh YY, et al. Real-world efficacy and safety of nebivolol in Korean patients with hypertension from the BENEFIT KOREA study. J Hypertens. 2020;38(3):527–35. https://doi.org/10.1097/HJH.0000000000002296.

    Article  CAS  PubMed  Google Scholar 

  26. Kallistratos MS, Poulimenos LE, Manolis AJ. Vasodilator/-blockers: a different class of antihypertensive agents? Futur Cardiol. 2014;10:669–71.

    Article  CAS  Google Scholar 

  27. Tomlinson B, Dalal JJ, Huang J, Low LP, Park CG, Rahman AR, Reyes EB, et al. The role of β-blockers in the management of hypertension: an Asian perspective. Curr Med Res Opin. 2011;27(5):1021–33. https://doi.org/10.1185/03007995.2011.562884.

    Article  CAS  PubMed  Google Scholar 

  28. Neupane D, McLachlan CS, Sharma R, et al. Prevalence of hypertension in member countries of South Asian Association for Regional Cooperation (SAARC): systematic review and meta-analysis. Medicine (Baltimore). 2014;93:e74.

    Article  Google Scholar 

  29. Kearney PM, Whelton M, Reynolds K, et al. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22:11–9.

    Article  CAS  Google Scholar 

  30. Ueshima H. Explanation for the Japanese paradox: prevention of increase in coronary heart disease and reduction in stroke. J Atheroscler Thromb. 2007;14:278–86.

    Article  Google Scholar 

  31. Ishikawa Y, Ishikawa J, Ishikawa S, et al. Prehypertension and the risk for cardiovascular disease in the Japanese general population: the Jichi Medical School Cohort study. J Hypertens. 2010;28:1630–7.

    Article  CAS  Google Scholar 

  32. Woodward M, Huxley H, Lam TH, et al. Asia Pacific Cohort Studies Collaboration. A comparison of the associations between risk factors and cardiovascular disease in Asia and Australasia. Eur J Cardiovasc Prev Rehabil. 2005;12:484–91.

    Article  CAS  Google Scholar 

  33. Park JB, Kario K, Wang JG. Systolic hypertension: an increasing clinical challenge in Asia. Hypertens Res. 2015;38:227–36.

    Article  Google Scholar 

  34. Kario K. Evidence and perspectives on the 24-hour management of hypertension: hemodynamic biomarker-initiated ‘anticipation medicine’ for zero cardiovascular event. Prog Cardiovasc Dis. 2016;59:262–81. https://doi.org/10.1016/j.pcad.2016.04.001.

    Article  PubMed  Google Scholar 

  35. Kario K, Tomitani N, Matsumoto Y, Hamasaki H, Okawara Y, Kondo M, Nozue R, Yamagata H, Okura A, Hoshide S. Research and development of information and communication technology-based home blood pressure monitoring from morning to nocturnal hypertension. Ann Glob Health. 2016;82:254–73. https://doi.org/10.1016/j.aogh.2016.02.004.

    Article  PubMed  Google Scholar 

  36. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, Watanabe M, Kadota A, Okuda N, Kadowaki T, Nakamura Y, Okamura T. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008;118:2702–9. https://doi.org/10.1161/CIRCULATIONAHA.108.790048.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Lawes CM, Bennett DA, Parag V, Woodward M, Whitlock G, Lam TH, Suh I, Rodgers A, Asia Pacific Cohort Studies Collaboration. Blood pressure indices and cardiovascular disease in the Asia Pacific region: a pooled analysis. Hypertension. 2003;42:69–75. https://doi.org/10.1161/01.HYP.0000075083.04415.4B.

    Article  CAS  PubMed  Google Scholar 

  38. Arima H, Murakami Y, Lam TH, Kim HC, Ueshima H, Woo J, et al. Effects of prehypertension and hypertension subtype on cardiovascular disease in the Asia-Pacific region. Hypertension. 2012;59:1118–23. https://doi.org/10.1161/HYPERTENSIONAHA.111.187252.

    Article  CAS  PubMed  Google Scholar 

  39. Katsuya T, Ishikawa K, Sugimoto K, Rakugi H, Ogihara T. Salt sensitivity of Japanese from the viewpoint of gene polymorphism. Hypertens Res. 2003;26:521–5.

    Article  Google Scholar 

  40. Kario K, Chen C, Park S, Park C, Hoshide S, Cheng H. Consensus document on improving hypertension management in Asian patients, taking into account Asian characteristics. Hypertension. 2018;71:375–82. https://doi.org/10.1161/HYPERTENSIONAHA.117.10238.

    Article  CAS  PubMed  Google Scholar 

  41. Avolio A. Genetic and environmental factors in the function and structure of the arterial wall. Hypertension. 1995;26:34–7.

    Article  CAS  Google Scholar 

  42. Reeve JC, Abhayaratna WP, Davies JE, Sharman JE. Central hemodynamics could explain the inverse association between height and cardiovascular mortality. Am J Hypertens. 2014;27:392–400. https://doi.org/10.1093/ajh/hpt222.

    Article  PubMed  Google Scholar 

  43. Kaess BM, Rong J, Larson MG, Hamburg NM, Vita JA, Levy D, Benjamin EJ, Vasan RS, Mitchell GF. Aortic stiffness, blood pressure progression, and incident hypertension. JAMA. 2012;308:875–81. https://doi.org/10.1001/2012.jama.10503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Ferdinand KC, Nasser SA. Understanding the importance of race/ethnicity in 462. The care of the hypertensive patient. Curr Hypertens Rep. 2015;17:15.

    Article  Google Scholar 

  45. Tu W, Pratt JH. A consideration of genetic mechanisms behind the development of hypertension in blacks. Curr Hypertens Rep. 2013;15:108–13.

    Article  Google Scholar 

  46. Turban S, Thompson CB, Parekh RS, Appel LJ. Effects of sodium intake and diet on racial differences in urinary potassium excretion: results from the Dietary Approaches to Stop Hypertension (DASH)-sodium trial. Am J Kidney Dis. 2013;61:88–95.

    Article  CAS  Google Scholar 

  47. Tu W, Eckert GJ, Hannon TS, et al. Racial differences in sensitivity of blood pressure to aldosterone. Hypertension. 2014;63:1212–8.

    Article  CAS  Google Scholar 

  48. Ozkor MA, Rahman AM, Murrow JR, et al. Differences in vascular nitric oxide and endothelium-derived hyperpolarizing factor bioavailability in blacks and whites. Arterioscler Thromb Vasc Biol. 2014;34:1320–7.

    Article  CAS  Google Scholar 

  49. Bennett A, Parto P, Krim S. Hypertension and ethnicity. Curr Opin Cardiol. 2016;31:381–6. https://doi.org/10.1097/HCO.0000000000000293.

    Article  PubMed  Google Scholar 

  50. Peng Y, Xue H, Luo L, Yao W, Li R. Polymorphisms of the β1-adrenergic receptor gene are associated with essential hypertension in Chinese. Clin Chem Lab Med. 2009;47:1227–31.

    CAS  PubMed  Google Scholar 

  51. RG Sy, Nevado JB Jr, Gonzales EM, Bejarin AJP, et al. A genetic polymorphism in GCKR may be associated with low high-density lipoprotein cholesterol phenotype among filipinos: A case-control study, acta medica Philippina, 2020. https://doi.org/10.47895/amp.vi0.2350.

  52. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part I. Clin Pharmacokinet. 2009;48:689–723.

    Article  CAS  Google Scholar 

  53. Nozawa T, Taguchi M, Tahara K, et al. Influence of CYP2D6 genotype on metoprolol plasma concentration and -adrenergic inhibition during longterm treatment comparison with bisoprolol. J Cardiovasc Pharmacol. 2005;46:713–20.

    Article  CAS  Google Scholar 

  54. Sohn D-R, Shin S-G, Park C-W, et al. Metoprolol oxidation polymorphism in a Korean population compared with native Japanese and Chinese populations. Br J Clin Pharmacol. 1991;32:504–7.

    Article  CAS  Google Scholar 

  55. Zhou HH, Koshakji RP, Silberstein DJ, et al. Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. N Engl Med. 1989;320:565–70.

    Article  CAS  Google Scholar 

  56. Rasool AHG, Rahman ARA, Ismail R, et al. Ethnic differences in response to non-selective beta blockade among racial groups in Malaysia. Int J Clin Pharmacol Ther. 2000;38:260–9.

    Article  CAS  Google Scholar 

  57. Huang KY, Tseng PT, Wu YC, Tu YK, Stubbs B, Su KP, et al. Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials. Sci Rep. 2021;11(1):452. https://doi.org/10.1038/s41598-020-79837-3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Marketou M, Gupta Y, Jain S, Vardas P. Differential metabolic effects of beta-blockers: an updated systematic review of Nebivolol. Curr Hypertens Rep. 2017;19(3):22. https://doi.org/10.1007/s11906-017-0716-3.

    Article  CAS  PubMed  Google Scholar 

  59. Münzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol. 2009;54:1491–9.

    Article  Google Scholar 

  60. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a betaadrenoceptor antagonist with unique characteristics. Drugs. 2007;67:1097–107.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Manila Doctors Hospital, Manila, Philippines

    Marie Barrientos-Regala & Joan Dymphna P. Reaño

Authors
  1. Marie Barrientos-Regala
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joan Dymphna P. Reaño
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Apollo Hospitals, Apollo Institute for Blood Pressure Management, Hyderabad, India

    C. Venkata S. Ram

  2. Head, Division of Nephrology Department of Medicine, Yong Loo Lin Sch of Med Natl Univ of Sin, Singapore, Singapore

    Boon Wee Jimmy Teo

  3. Department of Cardiology, Hero DMC Heart Institute, Dayanand Medical College, Ludhiana, Punjab, India

    Gurpreet S. Wander

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Barrientos-Regala, M., Reaño, J.D.P. (2022). Beta-Blockers for Hypertension in Asian Population. In: Ram, C.V.S., Teo, B.W.J., Wander, G.S. (eds) Hypertension and Cardiovascular Disease in Asia. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-030-95734-6_22

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-95734-6_22

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-95733-9

  • Online ISBN: 978-3-030-95734-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation